Schizophrenia

 

PANSS

Positive and Negative Syndrome Scale

Stanley R. Kay, Ph.D. , Lewis A. Opler, M.D., Ph.D. , Abraham Fiszbein, M.D.

Measure the positive and negative syndromes of schizophrenia to develop treatment plans

Overview

The Positive and Negative Syndrome Scale (PANSS™) is based on findings that schizophrenia comprises at least two distinct syndromes: the positive syndrome, consisting of productive symptoms; and the negative syndrome, consisting of deficit features. It is useful when developing treatment plans because you can focus on the type of symptoms the patient is experiencing. The PANSS is also helpful when studying the effects of medication (e.g., in clinical drug trials) because it allows you to determine which type of symptoms are being affected.

Key Areas Measured

  • Positive Scale
  • Negative Scale
  • General Psychopathology Scale
  • Supplemental Aggression Risk Profile

Key Areas Measured

 

MCCB

MATRICS Consensus Cognitive Battery

Keith H. Nuechterlein, Ph.D. , Michael F. Green, Ph.D.

A standardized battery for use with adults suffering from Schizophrenia and related disorders

Overview

The MATRICS Consensus Cognitive Battery (MCCB) is a standardized battery for use with adults suffering from Schizophrenia and related disorders. This is the only measure of cognitive performance that was developed under NIMH contract with participation from the U.S. Food and Drug Administration. It is recommended for all clinical trials of cognition-enhancing drugs for Schizophrenia.

Key Areas Measured

  • Speed of Processing
  • Attention/Vigilance
  • Working Memory (verbal)
  • Verbal Learning
  • Visual Learning
  • Working Memory (nonverbal)
  • Social Cognition
  • Reasoning and Problem Solving